Clinical Trials
Closed
Phase
SWOG Clinical Trial Number
S0309
Myeloma Specimen Repository Protocol, Ancillary
Research Committee(s)
Myeloma
Activated
11-15-2003
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0355
A Phase I Pharmacokinetic Study of Epothilone B Analogue BMS-247550 (NSC-710428D) in Patients with Advanced Malignancies and Varying Levels of Liver Dysfunction.
Status Notes
S0355 was permanently closed to accrual on 8/15/2006. All patient follow-up for S0355 concluded on 12/17/2007, and S0355 was added to the SWOG no-follow list at that time.
Please retain records until at least April 30, 2022. If your site has not already done so, all CTEP-supplied Epothilone B Analog (BMS-247550) must be immediately returned to the NCI Clinical Repository at 627 Lofstrand Lane, Rockville, MD 20850 ATTN: RETURNS. FDA regulations require all remaining supplies of this agent to be returned to the IND sponsor.
Please retain records until at least April 30, 2022. If your site has not already done so, all CTEP-supplied Epothilone B Analog (BMS-247550) must be immediately returned to the NCI Clinical Repository at 627 Lofstrand Lane, Rockville, MD 20850 ATTN: RETURNS. FDA regulations require all remaining supplies of this agent to be returned to the IND sponsor.
Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
11-01-2003
Closed
08-15-2006
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0221
"Phase III Trial of Continuous Schedule AC + G Vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High -Risk Node Negative Breast Cancer"
Status Notes
Effective immediately, the following S0221 Forms must be submitted in iMedidata RAVE: Follow-up Form, Supplemental Follow-up Form, S0221Trastuzumab Use Form, Notice of Death, Consent Withdrawal, and Lost to Follow-up. Rationale for change in data submission procedure, RAVE access, and data submission instructions are included in the 9/1/2020 memorandum, accessible from: www.ctsu.org.
Research Committee(s)
Breast Cancer
Activated
11-01-2003
Closed
01-15-2012
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0301
A Phase II Study of Induction With Daunorubicin, Cytarabine, and Cyclosporine All By Continuous IV Infusion for Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) in Patients of Age 56 or Older.
Research Committee(s)
Leukemia
Activated
10-01-2003
Closed
12-15-2006
Closed
Phase
Accrual
62%
Published
SWOG Clinical Trial Number
S0331
A Phase II Trial of STI-571/Imatinib (Gleevec®) (NSC-716051) in Neuroendocrine Carcinoma of the Skin (Merkel Cell Carcinoma)
Research Committee(s)
Melanoma
Activated
10-01-2003
Closed
03-01-2007
Closed
Phase
Accrual
56%
Published
SWOG Clinical Trial Number
S0230
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Research Committee(s)
Breast Cancer
Cancer Survivorship
Activated
10-01-2003
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0202
A Phase II Trial of Gemcitabine (NSC-613327) and Capecitabine (NSC-712807) in Patients with Unresectable or Metastatic Gallbladder or Cholangiocarcinoma
Research Committee(s)
Gastrointestinal Cancer
Activated
09-01-2003
Closed
04-01-2005
Closed
Phase
Accrual
63%
Published
SWOG Clinical Trial Number
S0222
A Phase II Study of Tirapazamine (NSC-130181)/Cisplatin/Etoposide and Concurrent Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
Research Committee(s)
Lung Cancer
Activated
09-01-2003
Closed
07-24-2006
Closed
Phase
Accrual
75%
Published
SWOG Clinical Trial Number
S0327
A Phase II Trial of PS-341 (NSC-681239) in Patients with Platinum-Treated Extensive Stage Small Cell Lung Cancer.
Research Committee(s)
Lung Cancer
Activated
09-01-2003
Closed
09-15-2004
Closed
Phase
Accrual
25%
SWOG Clinical Trial Number
S0322
Single Agent ZD-1839 in Patients With Advanced Head and Neck Carcinoma or Non-Small Cell Lung Cancer Aged 75 Years and Older (and in a Cohort of Patients 50 Years Old and Younger), Pharmacology.
Research Committee(s)
Early Therapeutics & Rare Cancers
Head and Neck Cancer
Lung Cancer
Activated
08-15-2003
Closed
02-15-2005
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0306
Phase II Study of Irinotecan in Patients with Advanced Transitional Cell Carcinoma of the Urothelium
Research Committee(s)
Genitourinary Cancer
Activated
07-15-2003
Closed
02-01-2007
Closed
Phase
Accrual
92%
Published
SWOG Clinical Trial Number
S0220
A Phase II Trial of Induction Chemoradiotherapy with Cisplatin/Etoposide Followed by Surgical Resection, Followed by Docetaxel, for Non-Small Cell Lung Cancer Involving the Superior Sulcus (Pancoast Tumors)
Research Committee(s)
Lung Cancer
Activated
07-01-2003
Closed
10-01-2007
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0317
A Phase II Study of OSI-774 (NSC-718781) in Patients with Locally Advanced or Metastatic Papillary Histology Renal Cell Cancer
Research Committee(s)
Genitourinary Cancer
Activated
05-01-2003
Closed
12-15-2005
Closed
Phase
Accrual
60%
SWOG Clinical Trial Number
S0117
A Phase II Study of Gemtuzumab Ozogamicin (Mylotarg™) and Standard Dose Ara-C for Patients With Relapsed Acute Myeloid Leukemia (AML)
Research Committee(s)
Leukemia
Activated
04-01-2003
Closed
10-15-2005
Closed
Phase
Accrual
0%
SWOG Clinical Trial Number
S0227
Phase III Randomized Trial of Cisplatin/Paclitaxel Versus Cisplatin/Gemcitabine in Recurrent, Persistent or Metastatic Carcinoma of the Cervix
Research Committee(s)
Gynecologic Cancer
Activated
04-01-2003
Closed
07-28-2003
Closed
Phase
Accrual
10%
SWOG Clinical Trial Number
S0125
A Phase II Study of Chimerism-Mediated Immunotherapy (CMI) Using Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation in Older Patients With Acute Myeloid Leukemia (AML) in First Complete Remission (A BMT Study)
Research Committee(s)
Leukemia
Activated
04-01-2003
Closed
06-01-2005
Closed
Phase
Accrual
22%
Published
SWOG Clinical Trial Number
S0011
Phase II Trial of Surgery with Perioperative INGN 201 (Ad5CMV-p53) Gene Therapy Followed by Chemoradiotherapy for Advanced, Resectable Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, Hypopharynx and Larynx
Research Committee(s)
Head and Neck Cancer
Activated
03-01-2003
Closed
07-01-2006
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0216
Docetaxel (NSC-628503), Cisplatin (NSC-119875), and 5-Fluorouracil (NSC-19893) Induction Chemotherapy Followed by Accerlerated Fractionation/Concomitant Boost Radiation and Concurrent Single Agent Cisplatin (NSC-119875), in Patients with Advanced Squamous Cell Head and Neck Cancer
Research Committee(s)
Head and Neck Cancer
Activated
03-01-2003
Closed
08-19-2004
Closed
Phase
Accrual
5%
SWOG Clinical Trial Number
S0025
Phase II Trial of Irinotecan (Camptosar) for Patients with Platinum and Taxane Refractory Ovarian, Peritoneal or Fallopian Tube Cancer
Research Committee(s)
Gynecologic Cancer
Activated
02-15-2003
Closed
08-15-2003
Closed
Phase
Accrual
48%
Published
SWOG Clinical Trial Number
S0030
Protocol for Assessment of Capecitabine for Advanced Colorectal Cancer in Patients Aged 70 Years and Older (and in a Cohort of Patients Younger than 60 Years)
Research Committee(s)
Gastrointestinal Cancer
Activated
02-01-2003
Closed
02-01-2005